|Day Low/High||2.88 / 2.93|
|52 Wk Low/High||2.46 / 6.18|
Booth to feature, a new ingredient introduction, information on the latest published clinical trials, and a new time-saving solution to ensure your products deliver on their promise
NR, a vitamin B3, affords food and beverage manufacturers a new opportunity to innovate
-Company Reports Record Revenue of $8.8 Million and Operating Income of $371,000-
-Company Will Host Investor Conference Call on Thursday, August 11, 2016-
Study results will help to define the effective dose range of nicotinamide riboside (NR) in humans when taken daily, over eight weeks.
Levi & Korsinsky announces it has commenced an investigation of ChromaDex Corporation ("ChromaDex" or the "Company") (NASDAQ:CDXC) concerning possible violations of federal securities laws.
Trade-Ideas LLC identified ChromaDex (CDXC) as a strong on high relative volume candidate
Goldberg Law PC ( http://www.Goldberglawpc.
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ChromaDex Corporation (NASDAQ:CDXC) resulting from allegations that ChromaDex may...
There is some good speculative trading and metals are the place to be.
New published study shows a unique form of vitamin B3, nicotinamide riboside, may help with weight gain and glycemic control as well as protect nerves from diabetic damage
Company Will Host Investor Conference Call on Monday, May 16, 2016